Skip nav

COVID-19 may have delayed deployment, but interest in PV automation remains strong – and would be higher still if companies could overcome the perception of poor solution choice, validation challenges, and the learning curve linked to adopting new processes

Dublin, Ireland – October 6, 2021 - Arriello, a provider of regulatory affairs, pharmacovigilance and auditing solutions and services for small to mid-sized biotech and pharma firms, has seen quality overtake price as a priority in plans for automating adverse event (AE) reporting, in its latest substantial pharmacovigilance automation survey conducted on both sides of the Atlantic.

The study also identifies fear for human jobs, along with validation issues, as a barrier to adoption – even though intelligent, digital case reporting offers to alleviate huge bottlenecks, drive up AE reporting reliability, and give valuable time...

Read full release

Image Channel